Condition: Cardiomyopathy Ischemic · Cardiomyopathies · Cardiovascular Diseases · Sponsor: Zoll Medical Corporation
The primary objective is to observe the rate of recovery of ventricular function (EF\>35%) after first-time coronary artery bypass graft surgery in patients who were prescribed the wearable cardioverter defibrillator (WCD) post-surgery prior to being discharged after hospitalization as part of standard clinical care.
This description comes directly from the study's public registry record.
Lars Weber, M.Sc. · 015161140498 · lweber@zoll.com
Horst-O. Esser · hesser@zoll.com
Always discuss trial participation with your own doctor first.
| Kerckhoff Klinik | Bad Nauheim, Hesse, Germany | Not Yet Recruiting |
| Medizinische Hochschule Hannover | Hanover, Lower Saxony, Germany | Recruiting |
| Sana-Herzzentrum Cottbus GmbH | Cottbus, Germany | Recruiting |
| Universitätsklinikum Halle (Saale) | Halle, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06570902